Journal article · 2019 · Open access

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer

Laura Jean Havrilesky, Jui‐Chen Yang, Paula S. Lee, Angeles Alvarez Secord, Jessie A. Ehrisman, Brittany Anne Davidson, Andrew Berchuck, Kathleen M. Darcy, George Larry Maxwell, Shelby D. Reed

Cancer, 125(24), 4399–4406 · Published 27 August 2019 · DOI 10.1002/cncr.32447

Open PDFView at the publisherCite this paper

In brief

“Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer” is a 2019 journal article by Laura Jean Havrilesky and 9 co-authors, published in Cancer. OpenAlex counts 30 citations as of 22 November 2026. It is open access: the full text is free to read at Cancer.

Citations
30
Most cited in
2020 (7)
Field-weighted impact
1.53
References
34
Authors
10

Abstract

BACKGROUND: Randomized trials have reported conflicting findings on survival for advanced-stage ovarian cancer treated with primary debulking surgery (PDS) versus neoadjuvant chemotherapy with interval debulking; surgical complications and mortality are higher with PDS. We assessed women's preferences for tradeoffs related to this important clinical decision. METHODS: Ovarian cancer patients were recruited to complete a discrete-choice experiment (DCE) consisting of 8 choice tasks presenting experimentally designed treatment alternatives in terms of treatment order, extent of surgery including risk of ostomy, chance of death from surgical complications (1%-10%), readmission for surgical complications (5%-50%), progression-free survival (1-3 years), and overall survival (3-5 years). Random-parameters logit regression was applied to model participants' choices as a function of attribute levels. RESULTS: A total of 101 ovarian cancer survivors completed the DCE survey; of these participants, 30% were receiving chemotherapy at the time, and 33% had prior recurrence. Overall survival was of greatest importance to participants (36/100), followed by risk of readmission due to complications (23/100), progression-free survival (19/100), surgical mortality (16/100), extent of surgery (4/100), and order of surgery and chemotherapy (2/100). Overall, the participants would tolerate a 15-percentage point increase in risk of major complications (95% confidence interval [CI], 3%-29%) or a 4-percentage point increase in the risk of surgical mortality (95% CI, 2%-13%) in order to increase their expected overall survival from 3 to 3.5 years. CONCLUSIONS: Patients would accept a moderately higher risk of perioperative complications and surgical mortality in exchange for substantial gains in survival. These quantitative findings provide clinicians with a framework to discuss preferences with patients and to incorporate preferences into clinical trial design.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Havrilesky, L. J., Yang, J., Lee, P. S., Secord, A. A., Ehrisman, J. A., Davidson, B. A., Berchuck, A., Darcy, K. M., Maxwell, G. L., & Reed, S. D. (2019). Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. Cancer, 125(24), 4399–4406. https://doi.org/10.1002/cncr.32447

MLA 9

Havrilesky, Laura Jean, et al. “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.” Cancer, vol. 125, no. 24, 2019, pp. 4399–4406. https://doi.org/10.1002/cncr.32447.

Chicago

Havrilesky, Laura Jean, Jui‐Chen Yang, Paula S. Lee, Angeles Alvarez Secord, Jessie A. Ehrisman, Brittany Anne Davidson, Andrew Berchuck, Kathleen M. Darcy, George Larry Maxwell, and Shelby D. Reed. 2019. “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.” Cancer 125 (24): 4399–4406. https://doi.org/10.1002/cncr.32447.

Harvard

Havrilesky, L. J. et al. (2019) ‘Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer’, Cancer, 125(24), pp. 4399–4406. doi:10.1002/cncr.32447.

IEEE

L. J. Havrilesky et al., “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer,” Cancer, vol. 125, no. 24, pp. 4399–4406, 2019, doi: 10.1002/cncr.32447.

BibTeX

@article{havrilesky2019patient,
  title     = {{Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer}},
  author    = {Havrilesky, Laura Jean and Yang, Jui‐Chen and Lee, Paula S. and Secord, Angeles Alvarez and Ehrisman, Jessie A. and Davidson, Brittany Anne and Berchuck, Andrew and Darcy, Kathleen M. and Maxwell, George Larry and Reed, Shelby D.},
  journal   = {Cancer},
  year      = {2019},
  volume    = {125},
  number    = {24},
  pages     = {4399--4406},
  doi       = {10.1002/cncr.32447},
  url       = {https://doi.org/10.1002/cncr.32447}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201911
202077
202133
202244
202311
202433
202566
202655

Its field-weighted citation impact is 1.53: it has been cited 1.53 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment

  • ovarian cancer
  • primary debulking surgery
  • neoadjuvant chemotherapy
  • interval debulking surgery
  • patient preferences
  • surgical complications
  • postoperative mortality
  • overall survival

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Havrilesky, L. J., Yang, J., Lee, P. S., Secord, A. A., Ehrisman, J. A., Davidson, B. A., Berchuck, A., Darcy, K. M., Maxwell, G. L., & Reed, S. D. (2019). Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. Cancer, 125(24), 4399–4406. https://doi.org/10.1002/cncr.32447

How many times has this paper been cited?

30 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Laura Jean Havrilesky, Jui‐Chen Yang, Paula S. Lee, Angeles Alvarez Secord, Jessie A. Ehrisman, Brittany Anne Davidson, Andrew Berchuck, Kathleen M. Darcy, George Larry Maxwell, Shelby D. Reed.

What is the DOI of this paper?

10.1002/cncr.32447, permanently at https://doi.org/10.1002/cncr.32447. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.